Control
Recent:Auld.
Jun 30 2023 |
et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-24482 | Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial |
| 11% higher mortality (p=1) and 49% longer hospitalization (p=0.09). RCT 40 critically ill COVID-19 patients showing no significant difference in outcomes with cyproheptadine. Cyproheptadine is a serotonin (5-HT) receptor antagonist, particularly at 5-HT2 receptors. Its effects may depend heavily on diseas.. | ||
Jan 4 2023 |
et al., CHEST Critical Care, doi:10.1016/j.chstcc.2025.100201 (results released 1/4/2023) | The Effects of Cyproheptadine on Severe COVID-19 From the ISPY-COVID Adaptive Platform Trial |
| 51% higher mortality (p=0.32), 206% higher combined mortality/intubation (p=0.002), and 122% worse recovery (p=0.004). RCT 96 critically ill COVID-19 patients in the USA showing higher mortality/ventilation and worse recovery with cyproheptadine. Anticholinergic adverse events (delirium, urinary retention, bronchial obstruction/atelectasis, ileus) were hi.. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.